Safety and efficacy of immunoguided prophylaxis for cytomegalovirus disease in low-risk lung transplant recipients in Spain: a multicentre, open-label, randomised, phase 3, noninferiority trial.

ABSTRACT:

Background

The standard prophylaxis treatment for cytomegalovirus (CMV) disease in CMV-seropositive lung transplant recipients is six months of prophylaxis with valganciclovir followed by six months of pre-emptive therapy. This protocol is associated with adverse events and risk of resistance. We have previously shown that prophylaxis can be suspended in CMV-seropositive kidney transplant recipients receiving thymoglobulin without increasing the risk of CMV disease and reducing the incidence of neutropenia. The objective of the current study is to demonstrate that immunoguided prophylaxis is effective and safe in seropositive lung transplant recipients.

Methods

A phase III, multicentre, randomised, open-label, noninferiority clinical trial was conducted in adult lung transpl

SUBMITTER: Paez-Vega A 

PROVIDER: S-EPMC11992424 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature